ARCA biopharma Inc
ABIO
Market Cap$34.82M
Close$
$2.58
91.1% downside
Current Fair Value
91.1% downsideOvervalued by 91.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $34.82 Million |
|---|---|
| Enterprise Value | $-44,262,816.00 |
| Dividend Yield | $3.18 (72.7291666666667%) |
| Earnings per Share | $-0.37 |
| Beta | 0.9 |
| Outstanding Shares | 41,680,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -46.73 |
|---|---|
| PEG | -4.94 |
| Price to Sales | - |
| Price to Book Ratio | 3.6 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.74 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | -0.1 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Oruka Therapeutics, Inc.
28 employees
CEO: Dr. Lawrence Otto Klein Ph.D. Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.